Trevi Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board introductions, five key proposals, and voting procedures. All proposals, including director election, auditor ratification, executive compensation, stock plan, and share increase, were approved. No questions were raised by shareholders.
-
A differentiated therapy for chronic cough is advancing through pivotal trials in IPF and RCC, with strong efficacy and safety data, a large addressable market, and a robust financial position to support development through 2030. Key data readouts are expected in 2027–2028.
-
The event outlined a focused strategy to lead in chronic cough with Haduvio, advancing pivotal trials in IPF, non-IPF ILD, and RCC, supported by strong financials and patent protection. Large, underserved markets and rapid physician adoption are expected, with peak sales potential of $6B across indications.
-
Clinical programs for IPF, non-IPF ILD, and RCC chronic cough are advancing, with strong cash reserves and extended runway into 2030. New patents strengthen IP, and key trial readouts are expected in late 2026 and 2027.
-
Strong Phase II results in chronic cough have set the stage for two pivotal Phase III trials, with FDA alignment on endpoints and timelines targeting NDA filing in about two and a half years. Expansion into non-IPF ILD and RCC, differentiated mechanism, and robust financial runway position the program for significant commercial impact.
Fiscal Year 2025
-
Major growth in 2025 was driven by positive clinical data and FDA alignment, enabling pivotal trials in IPF and non-IPF ILD chronic cough. With $188M in cash, the company is funded into 2028 to reach key milestones, including multiple phase III and IIb trial readouts.
-
Positive clinical data and a $115M capital raise have extended cash runway into 2028, supporting multiple late-stage trials in chronic cough indications. Q3 net loss narrowed to $11.8M, with strong investigator interest and regulatory alignment underway.
-
A single-asset company is advancing a mixed agonist-antagonist opioid drug for chronic cough in IPF, non-IPF ILDs, and RCC, with strong phase 2 data and a specialty-focused commercial strategy. Patent protection extends to 2039, and over $200 million in cash supports trials through 2028. FDA engagement and AI-driven operations are key priorities.
-
The company is advancing STAT3 inhibitors for IPF and oncology, with a pivotal IPF data readout expected in Q4 and HCC data in H1 2026. Interim trial results show promising lung function stabilization, and a next-generation prodrug is in development for improved delivery.
-
Strong CORAL and RIVER trial results enabled a $115M capital raise, boosting cash to $204M and funding late-stage trials into 2029. Haduvio showed significant efficacy and quality of life improvements in IPF cough, with Phase III and additional studies planned pending FDA alignment.
-
The CORAL phase 2b trial demonstrated that NAL ER significantly reduced chronic cough in IPF patients, with rapid, dose-dependent, and sustained effects, and a favorable safety profile. These results support advancing to phase 3 and expanding into non-IPF ILD chronic cough.
-
Strong phase II-A results in RCC and completion of CORAL trial enrollment highlight continued momentum. Net loss narrowed year-over-year, with cash runway into Q4 2026. Awaiting CORAL data to determine next steps and regulatory engagement.
-
Positive clinical results in both IPF and RCC cough support a central mechanism of action, with rapid onset and strong efficacy. The company is well-funded through 2026, planning pivotal trials and market expansion, and holds robust IP protection.
-
The phase II-A RIVER trial showed Haduvio significantly reduced cough frequency in refractory chronic cough patients, with robust efficacy across dose levels and patient subgroups, and a favorable safety profile. The differentiated mechanism and strong results support further development and a focused commercial strategy.
-
Upcoming clinical data for IPF and RCC are expected in the first half of the year, with Haduvio showing strong efficacy and a unique central mechanism. The company is well-funded, has robust patent protection, and is planning parallel pivotal studies with differentiated pricing strategies for each indication.
Fiscal Year 2024
-
Three positive clinical readouts in 2024 advanced Haduvio as a first-in-class therapy for IPF and RCC chronic cough, with robust trial execution and strong financial positioning. Phase II-B CORAL data is expected in Q2 2025, and cash runway extends into 2026.
-
Top-line results from the HAP study show nalbuphine has significantly lower abuse potential than a Schedule IV comparator, with no clear dose-response for abuse-related endpoints. Decades of real-world use and study data support maintaining its unscheduled status, with further regulatory discussions and clinical milestones ahead.
-
The presentation highlighted strong clinical progress in chronic cough and IPF, with promising efficacy data and multiple upcoming milestones. Both programs have significant market potential, and strategic interest is high as the company advances toward pivotal trials.
-
Clinical development advanced for chronic cough and IPF, with key data readouts expected in late 2024 and early 2025. Net loss widened to $13.2M in Q3 2024, with cash runway projected into 2H 2026. Multiple trials are fully enrolled and progressing toward pivotal milestones.
-
Strong phase II data in IPF cough showed a 75% reduction in cough frequency, with ongoing phase II-B and RCC studies expected to yield key data by early 2025. The drug's unique mechanism targets both central and peripheral pathways, and a solid cash position supports continued development.
-
Q2 2024 saw increased R&D and net loss as clinical trials in IPF and RCC advanced, with key data readouts expected in Q4 2024 and H1 2025. Cash runway extends into 2026, supported by a recent share issuance.